Introduction
The increased availability of antiretroviral therapy (ART) offers real hope of long-term survival to millions of HIV-infected individuals (World Health Organization, 2006) . However, in addition to access, strict adherence to ART regimes is critical for successful treatment (Bangsberg et al., 2000; Paterson et al., 2000) . Optimizing ART requires a deep understanding of the factors that impact patients' adherence, which can be highly contextual (Kumarasamy et al., 2005; Lewis, Colbert, Erlen, & Meyers, 2006; Malcolm, Ng, Rosen, & Stone, 2003; Malta, Petersen, Clair, Freitas, & Bastos, 2005; Powell-Cope, White, Henkelman, & Turner, 2003; Sankar, Golin, Simoni, Luborsky, & Pearson, 2006; Vervoort, Borleffs, Hoepelman, & Grypdonck, 2006) .
China is experiencing one of Asia's most serious HIV/AIDS epidemics (World Health Organization, 2006) . The Chinese government has made provision of free ART to qualifying patients a cornerstone of its HIV/AIDS policy (Qiang, 2003; Zhang, Hsu, Yu, Wen, & Two, 2004) , successfully providing ART to 18,000Á20,000 patients by the end of 2006 (World Health Organization, 2007) . Currently, efforts focus on expanding ART in border areas such as Yunnan, where the HIV epidemic remains concentrated among injection drug users (IDUs) (Yunnan Center for Disease Control, 2005) . Little is known about what factors influence ART adherence in China. To better understand adherence barriers faced by this population, we conducted a qualitative research study among Chinese patients, most of whom were former IDUs.
Methods
The study was conducted at the Dali Second People's Hospital (DSPH) in Old Dali, Yunnan province (population: 40,000), situated along a major heroin transit route from Vietnam and Myanmar. Respondents were sampled from among HIV-positive patients attending the DSPH Dermatology and Sexually Transmitted Diseases Clinic, which was selected in mid-2005 as a free ART site. Patients were eligible for participation if they were: (1) willing to provide informed consent; and (2) aged 18 years or above. Respondents participated in an in-depth interview (IDI), a focus group discussion (FGD) or both.
Procedures A team of local researchers with experience conducting qualitative research in China, who were provided additional training on HIV/AIDS, ART adherence and research ethics by the Boston-based and Beijing collaborators, collected data in Dali. The team identified potential respondents with assistance from DSPH clinicians. Two interviewers conducted each IDI/FGD, one facilitating the IDI/FGD and the other taking notes. All IDIs/FGDs took place in a location agreed upon by the respondent(s) and were conducted in Mandarin Chinese using semi-structured interview guides. We audio-recorded each IDI/FGD, a practice acceptable in China; these recordings did not appear to inhibit recruitment or in-depth discussion. Respondents were given a small stipend. The study was approved by ethical review boards at Boston University and Ditan Hospital, Beijing.
Questions addressed knowledge of HIV/AIDS and ART, barriers to medication-taking and circumstances related to episodes of non-adherence. Specific queries included: (1) How do you take your medications?; (2) Do you have any problems taking your medications and, if so, what are they?; and (3) What things might make it difficult for you to take your doses on time?
Data analysis
Recordings were transcribed and translated into English and supplemented by the note-taker's written observations. We coded and analyzed the English language transcripts using NVivo7 TM . Responses were prioritized by the frequency with which they were mentioned; the extent and nature of divergent views were also explored. Reports of specific challenges were included in the frequency analysis if a respondent mentioned the challenge as: (1) related to previous adherence experiences; (2) related to his/her HIV status or medication-taking behavior; or (3) a potential adherence issue for ART patients generally.
Results
Data were collected between December 2005 and March 2006. We conducted four focus groups (two with men, two with women) and 18 in-depth interviews (eleven with men, seven with women), with a total of 36 individual respondents (Table 1) . Just over threequarters of respondents had begun ART (n028), although the majority had only been on therapy for three to six months. All ART patients were on twicedaily regimens of nevirapine/efavarinz, lamivudine and stavudine/zidovudine. Patients obtained their medications on a monthly basis and were provided quarterly CD4 and viral load testing free of charge. All of the men (19/19), but a minority of the women (2/17), had contracted HIV through IDU. Aged 23 to 55 years, most respondents had a middle school education (nine years of schooling), typical of a semi-urban area in China, and lived with one or more family members, often parents or parents-in-law. About one-third were unemployed or retired.
Three dominant themes relating to potential adherence barriers emerged: stigma, mental health issues and financial concerns. Other less frequently mentioned barriers included forgetfulness, regimen-related problems and substance abuse. Table 2 summarizes the frequency of specific themes and sub-themes by gender. The major themes are discussed below, with supplemental statements by respondents provided in Table 3 .
Stigma
Stigma related to HIV/AIDS was by far the most commonly cited adherence challenge. Respondents expressed three sources of anxiety: (1) fear of disclosure of HIV status; (2) fear of work-related stigma; and (3) fear of stigma directed at family members.
Almost every respondent (32/36) conveyed intense fear of disclosure related to medication use. Dali, like most places in China, is densely populated. Respondents lived and worked in crowded conditions, making it difficult to ensure privacy at dose-taking times. Most had revealed their status only to close family members and friends, although some reported disclosure by doctors to family members without their permission. This did not accord with China's national laws governing AIDS prevention and treatment (Chinese Center for Disease Control and Prevention, 2006; State Council Legislative Affairs Bureau, 1988) , which prohibits disclosure of an individual's HIV status, but was not unusual in China's family-oriented culture. A few patients described keeping their status secret from family members to avoid worrying them or being ''blamed''. To prevent unwanted disclosure, respondents reported hiding their medications, disguising them, lying about them and delaying taking them. A 31-year-old married man explained, ''I fear other people will see me when I take medicine, and that wouldn't be good.'' Male respondents frequently mentioned stigma related to both IDU and HIV/AIDS. A 40-year-old married man made this typical statement: ''Drug users, it's a group that right now everyone in society hates. Including myself, I hate myself. But the problem is [that] there is nothing I can do.'' Several described using heroin again due to feelings of social isolation. In a male FGD, the group reflected on the difficulties ''drug users like us'' face in rejoining mainstream society as ART patients. A 36-year-old married man, apparently referring to official files held by local authorities on Chinese citizens that include records of imprisonment, labor re-education and drug detoxifica-tion, explained: ''We have the capabilities. We have the expertise. But locally we had some black marks in our records.'' Workplace stigma emerged as a major concern, both for men and women and for several unemployed respondents who anticipated working. Some had already felt humiliated by employers or co-workers. A single, 43-year-old woman reported open discussion by supervisors about her infection and described having to leave her job and turn to commercial sex work to support her child.
Most respondents sought to evade suspicion by concealing or disguising their pills at work. Given generally crowded circumstances, as well as China's traditional emphasis on collective welfare over individual privacy, many respondents found it difficult to keep their medication-taking secret at work. Respondents typically took their medications between 8:00Á 10:00 am/pm, when on route to work or already at work. Many insisted that it was best to avoid appearing sick at all. In one female FGD, the group agreed that wrapping the medications in paper was a good way to hide them at work. One man who worked in construction explained that he would delay taking his dose on some sites due to lack of privacy. A number of respondents (9/36) worried that their HIV status would cause members of their families, usually children or parents, to be stigmatized. For example, a 31-year-old man explained that he had disguised his medication bottles to protect his child. Others voiced concern about stigma directed toward their entire families. One 34-year-old married woman claimed, ''If they look down on me then they'll look down on my family. These damn farming communities are just like this.''
Mental health issues
Several mental health issues emerged as significant potential barriers to adherence. Three-quarters of respondents (27/36) described powerful feelings of sorrow, pain and/or pressure related to being HIV-positive. The most common words used to convey these emotions were: ''sad'', ''depressed'', ''gloomy'', ''unhappy'', ''in pain'' and ''psychological pressure''. Many women spoke of weeping for long periods and having trouble sleeping after learning of their status. A 27-year-old woman, whose husband and daughter were also HIVpositive, described her fears of death: ''I'll start crying. My child will give me some tissues to wipe my tears.''
One-third of respondents (12/36), seven men and five women, described feeling isolated. These feelings usually stemmed from self-imposed separation motivated by wishing to spare others HIV-related difficulties or shame. Many had kept secret their HIV status from loved ones, especially parents. Some had specifically asked Dali clinicians not to divulge this information to anyone. Others appeared to be socially isolated by the attitudes of family and friends. One Patients like with us, our kids are still young. We have duties. First, we have to take care of the old. Second, we have to bring up the young. We have to earn money for our family. We have to take care of our household. (29-year-old single man)
Importance of employment:
Only with a job can you survive in society and feed your family. We wish that we could live like everyone else Á work, live life. We don't want anyone to arrange any special jobs for us. respondent, a single, 31-year-old man not yet on ART, explained: ''I feel like a wall appeared between my family and me when they found out about my illness . . . I feel abandoned.'' Both men and women, but especially men, conveyed anxiety about not ''being normal''. One 32-year-old single man was worried about finding a wife, while many men equated being unable to find employment with being a social outsider. Women focused more on the isolating effects of ART. Several female respondents maintained that ART medications themselves made patients feel ''different'', ''disgusting'' or ''depressed''.
The men often articulated feelings of despair and guilt related to the previous needle-sharing that was responsible for their infections. Their remorse focused on the shame, financial hardship and risk of or actual infection they had inflicted on family members. They described disappointing their parents, who traditionally in China gain social status and financial security through their son(s)' accomplishments, as well as their failure to adequately support their wives and children. A 46-yearold married man seemed to express the views of an entire FGD: ''Because we are all drug users, the harm to the family is pretty great . . . This is a long-term guilt, when I think that it was my own mistake . . . I can't speak of any contribution to my family . . . I think about it a lot.''
When asked whether such feelings would affect their adherence, some said they would persevere with the medications regardless of their pain. They tended to describe their distress as a ''problem'' with therapy and implied, rather than stated directly, that the psychological ''burden'' of lifelong ART would discourage them from continuing their regimens. Some respondents, however, acknowledged that depression might hinder their adherence. One woman explained, ''If I'm happy today, I'll take the medicines. And tomorrow I won't take them. People like us . . . (broke down in tears)''.
Seven respondents, four women and three men, described recent thoughts of or attempts at suicide. Among the men, these admissions were accompanied by remorse at having disappointed or hurt family members. A single, 37-year-old man explained: ''I just wanted to disentangle and did not really want to go on. I just wanted to die. I was a burden for my family . . . I almost committed suicide.'' The women were particularly expressive in recounting grief, hopelessness and pain. A single, 28-year-old woman told of feeling ''life is meaningless''. One 34-year-old woman with children disclosed: ''Sometimes I don't want to see anyone. I just think if I die I can end it all.''
Economic issues
Most respondents reported economic worries related to their current medication-taking. Financial reliance on others was common, so lack of money was frequently raised as a major concern, particularly by We need to have jobs and an income or at least something to do on a daily basis. As long as we are busy, and our minds are occupied, there is no need for us to think about taking drugs. (36-year-old single man)
. . . if you say that you used to use drugs . . . they'll reject you. They don't understand at all how much these drug users need the job . . . it doesn't matter how much the compensation is, at the very least you'll be able to live. This is the most serious thing. You first have to have some security. (40-year-old married man) unemployed female respondents. However, even employed respondents discussed money pressures. Nearly two-thirds of respondents (23/36), 10/19 men and 13/17 women, identified the cost of ART medications as a significant issue. Although all respondents received ART free of charge, many stated that having to pay for ART would pose a critical adherence barrier. Most respondents reported constant ''worry'' or ''fear'' about possible future charges for the medications, which they equated with a virtual death sentence. A number of respondents recalled having to wait to begin therapy until the medications were freely provided; several had expected to pass away before that occurred. An entire female FGD group agreed on the ''big pressure'' they associated with paying for medications.
Although ART itself was free, other aspects of care remained costly. The most common charges discussed were for medical tests, treatment for side-effects and transportation to the clinic. Although public bus fares only appeared to be a problem for patients with no or few independent resources, tests and non-ART medications could be expensive (several hundred yuan, or more than $40) and represent a significant challenge even for working patients. A 36-year-old farmer explained, ''Sometimes I don't even have enough money to pay for the blood tests. I have to go home and ask my 60Á70year-old parents for money. It's a pretty bad feeling.'' Nearly all participants emphasized the importance of employment. About one-half of respondents (17/36, 14/19 men and 3/17 women), including most unemployed respondents and some part-time workers, revealed a powerful yearning for a job. Financial security, supporting themselves and their families, and a desire to be a ''normal'' member of society were the main reasons cited for wanting work. The men, in particular, agonized over the need for a secure income, while admitting that previous heroin use made finding employment difficult. Several respondents asserted that reliable employment was even more critical than ART medications. In a male FGD, the group agreed that it was vital to help everyone ''return to work in mainstream society'' because, as a 46-yearold married man concluded, compared with ART medications, ''Finding a job is more important''.
Discussion
The main barriers to adherence that we identified were stigma; mental health difficulties, including depression, anxiety and isolation; and economic worries. In addition, we found some salient gender differences in the experience of being HIV-positive and on ART.
Given previous studies in Africa and Asia that identified stigma as affecting ART patients (Kumar-asamy et al., 2005; Weiser et al., 2003) , we were not surprised to find stigma identified as a major issue in China. More remarkable was the multifaceted way that stigma was manifested and how intertwined it was with other factors influencing adherence. Patients were stigmatized by society at large, at work and by family members. Yet, fear of personal stigma was sometimes overshadowed by stigma directed at family members Á i.e. secondary stigma. Moreover, worries about stigma were linked with patients' psychological distress and financial problems, including difficulties finding employment. Much of this stemmed from fear of detection created by the need to store and take pills regularly, whether at home, on the bus, at work or while socializing. Notably, before patients began ART, their HIV status was relatively easy to keep secret. Afterward, dose-taking could threaten exposure and personal or family humiliation. One consequence was that some patients opted to delay or skip doses to avoid disclosing their infections, preferring ''saving face'' over actions that might extend their lives.
Similarly striking was the way in which HIV stigma overlapped with and magnified the shame associated with heroin use. Particularly among men, this dual stigma exacerbated difficulties in finding employment close to home and the Dali clinic, creating additional barriers to treatment. This suggests that in communities where HIV and IDU coexist, programs aimed at mitigating HIV-related stigma will be only marginally effective at supporting adherence unless they address IDU-related stigma. Coupling HIV management with heroin rehabilitation or methadone treatment may substantially improve treatment for patients with a history of heroin use. In addition, official sanction, even encouragement, of employing workers with a history of heroin detoxification might help address one of the key challenges former users face in reintegrating into society as ART patients.
There were important similarities observed among female respondents, few of whom were IDUs. In contrast with the men, whose previous Á and perhaps continued Á heroin use and HIV status complicated efforts to find work, the women were more worried about losing current jobs from disclosure of their HIV status. This is understandable, given that in urban and semi-urban areas like Dali, where the economy is relatively developed and families are small due to China's ''one child'' policy, women typically work fulltime in formal establishments Á factories, offices and stores Á rather than in informal businesses or farming. Their livelihoods and social roles, as well as their families' financial wellbeing, usually depend on their employment. Here, the need to conceal one's HIV status was just as significant an adherence barrier for women as for men. For both men and women, fear of work-based stigma sometimes superseded the need to take their HIV medications.
While not specifically defined as such, secondary stigma has been noted elsewhere as a potential barrier to adherence (Kumarasamy et al., 2005) . Our findings here are significant because they extend this issue to the China context and suggest a poignant irony. For male respondents, emotions expressed regarding family-related stigma were closely linked to feelings of guilt related to past, and perhaps continued, heroin use and a strong desire to provide for their families. Yet, in trying to protect their families' social standing by concealing their HIV status, these men may skip ART doses, potentially compromising their treatment and, ultimately, their ability to stay alive and provide for their families.
We observed a high frequency of mental health issues, although we did not conduct formal depression assessments. These issues have been described in the literature from the developed world (Abel & Painter, 2003; Hill, Kendall, & Fernandez, 2003; Remien et al., 2003; Westerfelt, 2004; Wood, Tobias, & McCree, 2004) , including among IDUs (Witteveen & van Ameijden, 2002) , but little has been published from developing countries. However, several studies have reported on the connection between depression and HIV status in African and Asian populations (Kaharuza et al., 2006; Mills et al., 2006; Ross, Sawatphanit, Suwansujarid, & Draucker, 2007; Sahay et al., 2007; Simbayi et al., 2007) as well as in China (Jin et al., 2006) . Our results extend this connection among developing country populations and add to the growing recognition of the importance and prevalence of mental health issues among HIV-positive Chinese individuals. The frequent mention of suicide as a potential recourse is notable, though perhaps not surprising given China's generally high rate of suicide (Phillips, Li, & Zhang, 2002; Zhang, Conwell, Zhou, & Jiang, 2004) . If such anxieties are widespread, we would argue for incorporating mental health screening into routine HIV care and treatment in China and evaluating the effectiveness of such interventions as support groups, which have proven useful elsewhere (Lyttleton, Beesey, & Sitthikriengkrai, 2007; Maher, Coupland, & Musson, 2007) but have not been widely adopted in China.
Other researchers have established a strong link between ART costs and adherence in developing countries (Crane et al., 2006; Kumarasamy et al., 2005; Weiser et al., 2003) . Given that our respondents were receiving ART free of charge, we were surprised at their frequently expressed worries about treatment costs. Most fears focused on a possible policy change regarding free ART, which would leave them without a source of medications. Additional concerns related to the many uncovered facets of care that patients bore themselves, including test costs, lost work time and travel costs, which, for patients with limited independent resources, represented a significant challenge. In this, they are like so many ART patients in other developing countries who need financial interventions to sustain ART over the long run.
Conclusion
In a population of Chinese HIV-positive patients with a high rate of IDU, primary and secondary stigma, mental health issues and financial concerns all emerged as key challenges to ART adherence. These factors were often interrelated and reinforced each other in complex ways. Optimizing adherence may require that ART programs be linked to other services, including drug addiction treatment, mental health services and vocational support. HIV care providers and policy makers in China should be aware of these important barriers to adherence. While provision of ''wrap around'' services involves cost and administrative effort, the long term socio-economic costs of increased HIV transmission and viral resistance that can result from sub-optimal ART adherence may be far greater.
